Geovax Labs Inc.

Geovax Labs Inc. is a biotechnology company focused on developing innovative vaccine technologies. The primary function of Geovax Labs is to create vaccines that address significant infectious diseases by leveraging their proprietary vaccine platform. This platform centers around the use of modified vaccinia Ankara (MVA) vector technology, designed to elicit robust immune responses. Geovax's vaccine developmental programs target various sectors, including infectious diseases like HIV, hemorrhagic fevers caused by viruses such as Ebola and Marburg, as well as vaccines for emerging infectious disease threats. Headquartered in the United States, the company plays a critical role in the biotechnology and pharmaceutical industry by aiming to provide effective health solutions through preventive vaccines. Its ongoing research and clinical trials are integral for meeting global health challenges, bolstering its market significance as an innovator within the vaccine development field. Through strategic collaborations and partnerships, Geovax Labs Inc. seeks to advance its vaccine candidates from research through to commercialization, addressing unmet medical needs and contributing to public health security.